Introducing Dx:Revenue - Precision Medicine Intelligence for Business Development Teams

LEARN MORE
Posts From the monthly archives: "May 2013"

Interesting survey (sponsored by Boehringer Ingelheim) of pulmonologists and pathologists regarding barriers to adoption of biomarker testing of lung cancer patients. Key finding: “Both pulmonologists and pathologists said the biggest challenges with biomarker testing include not always acquiring a tissue sample that is sufficient in size (60% and 73%, respectively) or quality (31% and 39…(Read More)